Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics Raises $6.6M in Share Placement

NEW YORK (GenomeWeb News) - Epigenomics said today that it has placed 2,671,088 new shares at an issue price of €1.94 per share, raising gross proceeds of €5.18 million ($6.6 million).

A subsidiary of BB Medtech and funds managed by Abingworth subscribed for all the new shares. The transaction will double the BB Medtech group's stake in Epigenomics to about 14.9 percent from about 7.4 percent, making it the second largest shareholder in the firm after Federated Investors. Funds managed by Abingworth will own about 11.1 percent of the company's shares.

The €1.94 issue price was a 5 percent premium over the volume-weighted average of the share price over the five trading days preceding the announcement of the placement.

Epigenomics said it plans to use the proceeds to develop and commercialize its blood-based molecular diagnostic for the early detection of colorectal cancer.

The company will also use the capital for clinical research and product development in its lung cancer and prostate cancer programs.

Filed under

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.